Using in vivo AAV-SB-CRISPR, researchers have identified CALHM2 as a key regulator of natural killer cell cytotoxicity, tumor infiltration, and cytokine production. CALHM2-KO CAR-NK cells showed strong antitumor effects in resistant solid tumor models. https://t.co/lYUk4kFtNz

Join us for the New Castle County Chamber of Commerce’s 2nd Annual State of the County on Tuesday, July 16, 2024, from 9-2 at University of Delaware’s Clayton Hall Conference Center. Eric Kmiec will be speaking on the institute's progress and future. https://t.co/daAnqOPrZH

The first therapy using CRISPR genome editing was approved in 2023 to treat blood disorders that affect thousands of people worldwide. But the approach is also a source of hope to many people who have rarer genetic conditions, like the one Uditi Saraf had. https://t.co/W85B2j063u

Researchers have developed a new method for precise target selection by using unusual type DEDD transposases. The method, seekRNA, is based on the IS1111 and IS110 insertion sequences and can be reprogrammed to target different sites. https://t.co/WG1WH1OIf4

New research shows that many CRISPR screening experiments rely on components, called CRISPR/Cas9 guides, that do not perform equally well in cells from people of all ancestries, which can cause CRISPR screens to miss cancer dependencies. https://t.co/nDB56IgBcB

It's that time again! We're proud to see Eric Kmiec speak at the Leadership Delaware Speaker Series, highlighting key members of Delaware's innovative political, business, and scientific leaders. Learn more about LeadershipDel's series model below! https://t.co/aAL0LC9C1x

A gene-editing technique has shown modest success at treating a blindness disease, according to results from a clinical trial published today in The New England Journal of Medicine. https://t.co/Vjt6sW1i0r

Read how the grassroots efforts of 'In our DNA SC' use brochures and spit to change the percentage of DNA from non-white patients is in the research pool. https://t.co/rVe8BbIuFR

Intellia Therapeutics says that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated. https://t.co/Bu1E6jscHO

We're proud to celebrate our progress in bringing gene editing solutions to hurdles in healthcare. Now, it begs asking: where do we belong in the regional conversation on gene editing? Where does Delaware as a whole fit in? Read more below: https://t.co/Wzq2xsXjBk

CRISPR’s novel harnessing of bacterial proteins to target disease-carrying genes has reshaped medical research. But there’s a significant impediment to maximizing CRISPR’s potential for developing therapies: lack of diversity in genetics research. https://t.co/xZJO5BMabA

We look forward to seeing Eric Kmiec, Ph.D., share his findings and insights on CRISPR in healthcare at the World Congress of In Vivo Biology in St. Louis, MO. Get your tickets before it's too late! https://t.co/WXcfjzsskt

Time is running out to get tickets to the World Congress on In Vivo Biology! See Eric Kmiec, Ph.D., discuss our current methodologies and goals for in vivo gene editing to assist in cancer care. Learn more below! https://t.co/WXcfjzsskt

The Food and Drug Administration approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, marketed as Beqvez, for adults with hemophilia B. https://t.co/2xTLpmdAb5

Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated. https://t.co/0V3c35MqhK

Eric Kmiec, Ph.D., will be presenting the team's research on CRISPR-directed gene editing at the 2024 World Congress on In Vitro Biology on Monday, June 10th. We're excited to see this research take the St. Louis stage! Learn more below. https://t.co/WXcfjzsskt

Our research takes center stage at ASGCTherapy's 2024 conference! Nicole Haas and Kristen Pisarcik, both doing groundbreaking gene editing work on non-small cell lung tumors to extend patient survival, are presenting their poster today in the main hall. Go check it out! https://t.co/VopjCPmHcf

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. https://t.co/Nb7OHbAbJN

New A.I. technology is generating blueprints for microscopic biological mechanisms that can edit your DNA, pointing to a future when scientists can battle illness and diseases with even greater precision and speed than they can today. https://t.co/JDOfPvJ1GY

Physicians at ChildrensPhila restored eyesight in two children by performing a gene therapy technique to correct a genetic mutation causing blindness, a first-of-its-kind treatment. We're proud to promote our neighbor's work in the field! https://t.co/pjsznZy6TS

The ambitious idea of using CRISPR to cure genetic diseases before birth is one step closer to reality. Scientists have reported a use of technology known as “base editing” to alter the DNA of laboratory monkeys in the womb to treat a deadly liver disease. https://t.co/2uylEdh4iB

Delaware's DNA Conference is coming next week, and there's still time to get tickets! Join life science leaders in the Delaware area, including Kelly Banas, Ph.D., who will be presenting on her research toward better cancer treatments using gene editing. https://t.co/ju7k4laR2E

Happy Employee Appreciation Day! At the Gene Editing Institute, we're committed to advancing healthcare through the use of CRISPR to fill areas of unmet need. We'd be nowhere without our team of creative, innovative, and enthusiastic scientists and educators. Thank you, team!

It’s Wear Red Day at the Gene Editing Institute! We’re proud to support our caregivers and colleagues at christianacare , and we take today to give awareness to those suffering from heart disease. Every research step we take in the lab is to improve treatments for patients, but there’s things we can do every day to help our community. Today, we’re wearing red! Thank you to our fellow caregivers; spread the love!

We are so excited to see Eric Kmiec, Ph.D., on 'For the Love of Health', the ChristianaCare podcast dedicated to exploring healthcare's new groundbreaking treatments and innovations. In this episode, Kmiec spoke about the use of CRISPR in cancer care and how we can educate our community. Check it out at ChristianaCare.org/podcasts or on your favorite podcast app. #STEM #CRISPR #LoveofHealth

It seems that we had a witch in the lab yesterday! She brewed up a lab-safe potion that the whole team enjoyed (from a distance). Happy Halloween! (Thanks Nicole Haas for giving us a little lesson on dry ice!)

We're proud to announce that Eric Kmiec, Ph.D., our chief scientific officer, has been named the Editor in Chief of Gene and Genome Editing, an Elsevier journal! Read more about the developments to come for this prestigious publication below. We're proud to incorporate the expertise of our peers and colleagues in the gene editing community into this journal, and we look forward to shaping its future together.

Yesterday, we met with IP attorneys Basil Krikelis and Jeff Saffron from McCarter & English LLP, who talked to us about the intricacies of patent law and what steps it takes for our research to get to the patent office. This is an important step for any research institute, and we want to stay informed about what it takes to make and protect a patent. Thanks for the presentation!

Scientists have long known that cancer cells typically have extra chromosomes, but what exactly was the extra genetic material doing? According to a team at Yale, these extra chromosomes are used to boost tumor growth and could be targeted as a new pathway for cancer treatment.

The collaboration leverages Scribe’s proprietary CRISPR X-Editing technologies and Sanofi’s targeted non-viral delivery technologies for the treatment and prevention of genetic disorders, starting with the in vivo treatment of SCD, an inherited blood disorder thought to affect between 70,000 and 100,000 U.S. residents. While ex vivo therapies require cells collected from a patient to then be genetically modified in the lab and eventually returned to the patient, in vivo therapies use certain methods that directly modify genes within a patient’s cells.